Jazz Collaborates with Redx Pharma to Develop Two Targeted Cancer Therapies

 Jazz Collaborates with Redx Pharma to Develop Two Targeted Cancer Therapies

Jazz Collaborates with Redx Pharma to Develop Two Targeted Cancer Therapies

Shots:

  • Redx to receive $10M as up front followed by another $10M in year two and will receive up to $400M as milestones along with royalties on sales of the therapies. The first milestone is payable following IND submission
  • Following a successful IND submission, Jazz will be responsible for further development, manufacturing, regulatory activities, and commercialization. The two companies will discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway
  • The collaboration follows sale of Redx’s pre-clinical pan-RAF inhibitor program to Jazz for the treatment of Raf and Ras mutant tumors in July’2019

Click here ­to­ read full press release/ article | Ref: Jazz Pharmaceutical  | Image: Getty Images

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post